Splash
Splash

News & SEC Filings

News

View all news
14 May 2020Company News, Regulatory
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has received written comments from the U.S. Food and Drug Administration (FDA) in response to its End-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (“COPD”).

12 May 2020Regulatory
Director/PDMR Shareholding - Grant of Restricted Stock Units, Issue of Equity, Total Voting Rights & PDMR Dealings

LONDON, May 12, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it has on May 7, 2020 granted to

1 May 2020Regulatory
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted demonstrating ensifentrine’s potential across treatment settings and formulations LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Verona

30 April 2020Regulatory
Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces financial results for the three months ended March 31, 2020, and provides a corporate update. Conference call today at 9:00 am EDT / 2:00 pm BST.

23 April 2020Regulatory
Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

LONDON, April 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its financial results for the three months ended March 31, 2020 on Thursday, April 30, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss the financial results and provide a corporate update.

SEC Filings

Group

Year

DateDescriptionFormFiling GroupView
14 May 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
30 Apr 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
30 Apr 2020Securities offered to employees pursuant to employee benefit plansS-8Registration Statements
16 Apr 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
14 Apr 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
06 Apr 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
30 Mar 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
10 Mar 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
27 Feb 2020Registration of securities of foreign private issuers pursuant to section 12(b) or (g)20-FAnnual Filings
05 Feb 2020An amendment to the SC 13G filingSC 13G/AOther
04 Feb 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
17 Jan 2020Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
29 Nov 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
22 Nov 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
22 Nov 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
05 Nov 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
19 Sep 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
14 Aug 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
08 Aug 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
07 Aug 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
05 Jun 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
14 May 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
07 May 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
03 May 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
12 Apr 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
02 Apr 2019Filing by person(s) reporting owned shares of common stock in a public company >5%SC 13DOther
26 Mar 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
26 Mar 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
19 Mar 2019Registration of securities of foreign private issuers pursuant to section 12(b) or (g)20-FAnnual Filings
12 Mar 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
28 Feb 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
12 Feb 2019An amendment to the SC 13G filingSC 13G/AOther
11 Feb 2019An amendment to the SC 13G filingSC 13G/AOther
04 Jan 2019Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
06 Nov 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
25 Sep 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
14 Aug 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
07 Aug 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
28 Jun 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
04 Jun 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
01 Jun 2018EFFECTEFFECTOther
22 May 2018Registration statement for certain foreign private issuers offered for certain transactionsF-3Registration Statements
08 May 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
04 May 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
04 May 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
18 Apr 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
29 Mar 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
22 Mar 2018Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
27 Feb 2018Annual Report of foreign issuer rules 13 and 15(d) of the Securities Exchange Act20-FAnnual Filings
13 Feb 2018An amendment to the SC 13G filingSC 13G/AOther
06 Feb 2018An amendment to the SC 13G filingSC 13G/AOther
26 Jan 2018An amendment to a SC 13D filingSC 13D/AOther
09 Nov 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
21 Sep 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
12 Sep 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
24 Aug 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
08 Aug 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
26 May 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
18 May 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
12 May 2017A statement of beneficial ownership of common stock by certain personsSC 13GOther
09 May 2017Filing by person(s) reporting owned shares of common stock in a public company >5%SC 13DOther
09 May 2017A statement of beneficial ownership of common stock by certain personsSC 13GOther
08 May 2017A statement of beneficial ownership of common stock by certain personsSC 13GOther
08 May 2017Filing by person(s) reporting owned shares of common stock in a public company >5%SC 13DOther
08 May 2017Filing by person(s) reporting owned shares of common stock in a public company >5%SC 13DOther
05 May 2017A statement of beneficial ownership of common stock by certain personsSC 13GOther
05 May 2017A statement of beneficial ownership of common stock by certain personsSC 13GOther
03 May 2017Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act6-KCurrent Reports
01 May 2017CT ORDERCT ORDEROther
28 Apr 2017Securities offered to employees pursuant to employee benefit plansS-8Registration Statements
28 Apr 2017Form of prospectus disclosing information facts events covered in both forms 424B1 424B3424B4Registration Statements
26 Apr 2017This filing is a pre-effective amendment to an F-1 filingF-1/ARegistration Statements
26 Apr 2017Registration of up to an additional 20% of securities for an offering filed on an F-1F-1MEFRegistration Statements
26 Apr 2017EFFECTEFFECTOther
26 Apr 2017EFFECTEFFECTOther
21 Apr 2017CERTNASCERTNASOther
19 Apr 2017CERTNASCERTNASOther
19 Apr 2017Registration of certain classes of securities 12(b) of the Securities Exchange Act8-A12BRegistration Statements
18 Apr 2017This filing is a pre-effective amendment to an F-1 filingF-1/ARegistration Statements
18 Apr 2017Registration of depository shares evidenced by American Depository ReceiptsF-6Registration Statements
03 Apr 2017Registration statement for certain foreign private issuersF-1Registration Statements
13 Feb 2017A statement of beneficial ownership of common stock by certain personsSC 13GOther
20 Jul 2016-DOther
Splash

© Verona Pharma plc 2020. All rights reserved